Novavax Sees Unusually Large Options Volume (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) was the recipient of some unusual options trading activity on Wednesday. Stock traders purchased 19,222 put options on the company. This represents an increase of 48% compared to the typical daily volume of 12,997 put options.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. purchased a new stake in Novavax during the fourth quarter worth $27,000. Spire Wealth Management acquired a new position in Novavax in the 4th quarter worth about $29,000. New Age Alpha Advisors LLC purchased a new position in Novavax during the fourth quarter worth approximately $35,000. KBC Group NV increased its position in shares of Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 3,917 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Novavax by 2,272.5% during the 1st quarter. GAMMA Investing LLC now owns 11,839 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 11,340 shares during the period. 53.04% of the stock is owned by institutional investors and hedge funds.

Novavax Trading Down 2.5 %

Shares of NVAX stock traded down $0.16 during mid-day trading on Wednesday, reaching $6.23. The stock had a trading volume of 1,980,719 shares, compared to its average volume of 8,189,805. Novavax has a 1-year low of $3.81 and a 1-year high of $23.86. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -2.76, a PEG ratio of 2.85 and a beta of 3.15. The business’s fifty day moving average is $7.39 and its 200-day moving average is $8.73.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.24. The business had revenue of $88.31 million for the quarter, compared to analyst estimates of $85.48 million. During the same quarter in the previous year, the firm posted ($1.44) earnings per share. On average, analysts forecast that Novavax will post -1.46 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on NVAX shares. TD Cowen upgraded Novavax to a “hold” rating in a report on Thursday, February 27th. BTIG Research assumed coverage on Novavax in a research report on Friday, February 28th. They issued a “buy” rating and a $19.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $18.00.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.